pcl1029

Hi, everyone,

In one of the immunology session ,experts had reviewed about 25 posters that they picked out for their worthiness. All of them are about other diseases,but the one the experts that are in the immunology field picked out ; title “Adoptive T-cell therapy(ACT) with TILS for metastatic melanoma:clinical responses and durable persistence of anti-cancer responses in peripheral blood(abstract 3026)” by M Donia et,al. the expert concluded that this is the most promising abstract for treatment of melanoma in immunology. I remember one of our member was on this treatment for CCA at NIH and shown good long term releive of symptoms until recently.( I think the disease free period for her is around one year with only one treatment.)
In short I think ACT with TIL for treatment for CCA may be relatively a good alternative treatment if other treatment plan are exhausted.( I think the clinical trial is still open.)

The use of calcium and magnesium IV infusions in the treatment of cancer like colon cancer didnot make any significant change or shown benefits in the overall protective and preventive treatment for neuropathy toxicity caused by oxaliplatin.

There are no significant benefit for using Avastin in colon cancer due to the high cost and the overall survival difference of 8 weeks may not be worth it.

Therare only a 3% difference in the preventive follow up monitoring among using CEA test only;CEA test+CT scan or Ct scan alone after colon resection.

There is no significant difference between using Xyloda twice daily as maintenance therapy and observatioon alone in the preventiion of recurrence of colon cancer.( from the dutch cancer foundation study); irinotecan will the 2nd line treatment if disease progress.

NLR( the ratio of neutrophil/lymphocyte)>/ may be useful as a prognostic marker for biliary cancer recurrence especially for extrahepatic cholangiocarcinoma; they are still working on whether the same principle will be applied to ICCA.( BTW, this is a continuing research study at Mass General).

The number one biliary treatment center in Hong Kong is the Queen Mary Hospital affilitated with the University of Hong Kong.

There is a poster from MSK from New York about “Hepatic Arterial Infusion for Unresectable Cholangiocarcinoma” ; I will put up the update on this poster later.But the interesting facts is that ,through the exchange of ideas between me and the presenter,who is a surgerical fellow doctor working with Dr. Fong, to whom some of our board membersw were treated by Dr.Fong. Base on what I can understand, Dr. fong is investigating to use robotic (ie: the Devinci robotic system) to perform liver resections,start with small tumors first , so this may be a new way to come in addition to use the arterial pump with FUDR.

In one poster study, It shows there were no difference in UK and Japan with regard to the efficacy in using GEM/CIS , both in OS and PFS.

God bless.

Hi, everyone,
This morning, I attend another lecture on “Recently Approved Agents”,
there are
1. Regorafenib by George Blumrnchein from MD Anderson;it is used for refractory colon cancer; regorafenib is for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy.

2.TDM-1 ,by Howard Burris from Sarah Cannon Research Institute;it is used for GIST and breast cancer for the treatment of patients with HER2-positive (HER2+), metastatic breast cancer (MBC) who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: Received prior therapy for metastatic disease, or
Developed disease recurrence during or within six months of completing adjuvant therapy.
3. Pertuzumab by Michael Gordon from Pinnacle Oncology Hematology;it is used for in combination with Herceptin (trastuzumab) and docetaxel chemotherapy for people with HER2-positive metastatic or locally recurrent, unresectable breast cancer, who have not received previous treatment or whose disease has relapsed after adjuvant therapy.
4.Enzalutamideby Charlse Ryan from UC at San Francisco;it is used for prostate cancer. enzalutamide is for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.
5. Ruxolitinib by Srdan Verstovsek ,MD Anderson; it is used for the treatment of intermediate and high risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosisbrosis.

6.Ponatinib by Jorge Cortes from MD Anderson; it is used for CML; to treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.

7. Carfilzomib by Kyriakos Papadopoulos from START Center for Cancer Care; it is for myeloma.It is for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the completion of the last therapy.

None of the new drugs are for either the liver or CCA.

This year ,ASCO make the molecular landscape of cancer by using “PANOMICS’ as one of the three “drivers of change”.

Panomics is defined as the understanding of the complex combination of genes, proteins, molecular pathways and the unique patient characteristics that together drive the disease of cancer,as well as
an understanding of how to target these factors in combination to develop prevention strategies and curative therapies.

God bless.